Comment on ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’...

por Charbonneau, C, Sandin, R
Publicado 2010

Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008)

por Wahlgren, T, Harmenberg, U, Sandström, P, Lundstam, S, Kowalski, J, Jakobsson, M, Sandin, R, Ljungberg, B
Publicado 2013

Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer

por Tombal, B., Sternberg, C.N., Hussain, M., Ganguli, A., Li, Y., Sandin, R., Bhadauria, H., Oh, M., Saad, F.
Publicado 2022